HALO
Halozyme TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
12
U.S. public peers
Grade Position
In line
vs peer average
HALO vs peer average
51/100
HALO vs. peer average (C vs. C)
Grade spread
A 2 · B 3 · C 2 · D 2 · F 3
Graded peers loaded
Coverage
12 graded
100% of tracked
Peer overview
RPRX is the first available peer comparator.
Direct royalty-business comparator: Royalty Pharma is a biopharmaceutical royalty funder and buyer with royalty receipts as its core operating exposure. It provides a useful reference for royalty economics but lacks Halozyme's drug-delivery platform exposure. [Royalty Pharma](https://www.royaltypharma.com/our-firm/)
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
HALO
Halozyme Therapeutics
RPRX
Royalty
Grade
C
D
Momentum
97
91
Value
63
62
Sentiment
41
30
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Defensive
Grade position vs RPRX
HALO / RPRX
Grade Position
In line
HALO vs. peer average (C vs. C)
51/100
Momentum
97
HALOValue
63
HALOSentiment
41
HALORotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs HALO
RPRX is the first peer returned for this comparison set.